Funded Startups in Laguna Hills
Across Laguna Hills, one disclosed round stands out in size: Arthrosi Therapeutics raised $61M on 2025-06-23, which sits above the rest of the disclosed am…
Across Laguna Hills, one disclosed round stands out in size: Arthrosi Therapeutics raised $61M on 2025-06-23, which sits above the rest of the disclosed amounts shown (the next-largest is Sonendo at $63M on 2022-09-23, while all other disclosed rounds are $21M or lower). The list also shows temporal clustering: three of the eight disclosed rounds fall between 2022-01-03 and 2022-04-13 (Amberstone Biosciences $12M, PharmaCyte Biotech $15M is earlier in 2021, and Hallux $9M), and half of the entries are biotechnology across different series labels.
Sector and stage signals are mixed but concentrated in one area: 6 of 8 companies are listed in Biotechnology (Arthrosi Therapeutics, Sonendo, Hallux, Prelude, Amberstone Biosciences, PharmaCyte Biotech). Series classification appears heavily as “Series Unknown” for 5 of 8 entries, with the two “Post-IPO Equity” rounds (Sonendo on 2022-09-23 at $63M and PharmaCyte Biotech on 2021-08-12 at $15M) forming a smaller, older cluster. Dates span 2021-08-12 (PharmaCyte Biotech) through 2025-06-23 (Arthrosi Therapeutics).
Most recent rounds
8 shownRelated listings
Frequently asked
What is the biggest disclosed round in these Laguna Hills entries, and how does it compare to the rest?
Sonendo’s $63M round on 2022-09-23 is the largest disclosed amount in the eight rows. The only other disclosed amounts above $50M are Arthrosi Therapeutics’ $61M on 2025-06-23; all remaining disclosed rounds are $21M or lower (with Strike Acceptance at $21M on 2024-02-13 the highest after those two).
Are there any date-window clusters among the most recent rounds shown?
Yes. Four of the eight disclosed rounds are in 2022 (Amberstone Biosciences on 2022-01-03 for $12M, Prelude on 2022-03-22 for $20M, Hallux on 2022-04-13 for $9M, and Sonendo on 2022-09-23 for $63M). The other entries bookend the window with 2021-08-12 (PharmaCyte Biotech, $15M) and 2024-02-13 (Strike Acceptance, $21M), plus the most recent 2025-06-23 (Arthrosi Therapeutics, $61M).
Is Biotechnology over-represented compared with other sectors in this city list?
Biotechnology appears in 6 of the 8 entries (Arthrosi Therapeutics, Sonendo, Hallux, Prelude, Amberstone Biosciences, PharmaCyte Biotech). The remaining 2 entries are Health Care (Adagio Medical, $10M on 2022-11-08) and Commerce and Shopping (Strike Acceptance, $21M on 2024-02-13), with no other sectors repeating in the visible rows.
Which stage classifications dominate, and are there notable outliers in stage labeling?
“Series Unknown” is the most common label, covering 5 of the 8 rows (Arthrosi Therapeutics 2025-06-23 $61M; Strike Acceptance 2024-02-13 $21M; Adagio Medical 2022-11-08 $10M; Hallux 2022-04-13 $9M; and Prelude 2022-03-22 $20M). The two “Post-IPO Equity” entries are outliers in label and timing relative to the many Series Unknown rows: Sonendo ($63M on 2022-09-23) and PharmaCyte Biotech ($15M on 2021-08-12).
What concentration exists in the smallest disclosed rounds, and what’s the lowest disclosed amount overall?
The smallest disclosed amount in the table is $9M for Hallux on 2022-04-13. It’s in the same lower range as Adagio Medical’s $10M on 2022-11-08, while the rest of the disclosed rounds skew higher, including mid-teens levels (Amberstone Biosciences $12M on 2022-01-03; PharmaCyte Biotech $15M on 2021-08-12) and two much larger rounds above $50M (Sonendo $63M and Arthrosi Therapeutics $61M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.